Advanced search
Publication Cover
Leukemia & Lymphoma Volume 45, 2004 - Issue 4
Submit an article Journal homepage
57
Views
21
CrossRef citations to date
0
Altmetric
Original Article

High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Stem Cell Support: a New Regimen for the Treatment of Multiple Myeloma

Michele L Donato Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USACorrespondence[email protected]
,
Ana Aleman Department of Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
,
Richard E Champlin Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
,
Donna Weber Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
,
Raymond Alexanian Department of Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
,
Cindy M Ippoliti Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
,
Marcos De Lima Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
,
Athanasios Anagnostopoulos Department of Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
&
Sergio Giralt Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
 show all
Pages 755-759 | Received 10 Jul 2003, Published online: 03 Aug 2009

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Kalyan Nadiminti, Kamal Kant Singh Abbi, Sarah L Mott, Lindsay Dozeman, Annick Tricot, Allyson Schultz, Sonya Behrends, Fenghuang Zhan & Guido Tricot. (2017) VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma. OncoTargets and Therapy 10, pages 217-226.
Read now
Badran Abu Zaid, Ali Abdul-Hai, Itamar Grotto, Lillian Dray, Igor B. Resnick, Panagiotis D. Tsirigotis, Simcha Samuel, Reuven Or & Michael Y. Shapira. (2013) Autologous transplant in multiple myeloma with an augmented conditioning protocol. Leukemia & Lymphoma 54:11, pages 2480-2484.
Read now
Morie A Gertz, Martha Q Lacy, Angela Dispenzieri, Suzanne R Hayman & Shaji K Kumar. (2006) High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Review of Anticancer Therapy 6:3, pages 343-360.
Read now
Jingyan Jiang, Beihua Kong, Baijun Shen, Li Li, Xingsheng Yang, Huaishui Hou, Qing Shi, Daoxin Ma & Xiufeng Ma. (2005) High Dose Chemotherapy and Transplantation of Hematopoietic Progenitors from Murine D3 Embryonic Stem Cells. Journal of Chemotherapy 17:3, pages 302-308.
Read now
Karen Seiter. (2005) Toxicity of the topoisomerase I inhibitors. Expert Opinion on Drug Safety 4:1, pages 45-53.
Read now

Articles from other publishers (16)

Mohammad O Ali & Samer Al Hadidi. (2022) High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma. Transplantation and Cellular Therapy 28:9, pages 572-580.
Crossref
Francesca Fontana, Michael J. Scott, John S. Allen, Xiaoxia Yang, Grace Cui, Dipanjan Pan, Noriko Yanaba, Mark A. Fiala, Julie O'Neal, Anne H. Schmieder-Atteberry, Julie Ritchey, Michael Rettig, Kathleen Simons, Steven Fletcher, Ravi Vij, John F. DiPersio & Gregory M. Lanza. (2021) VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival. Clinical Cancer Research 27:7, pages 1974-1986.
Crossref
Alexandra Gomez-Arteaga, Tomer M. Mark, Danielle Guarneri, Paul J. Christos, Usama Gergis, June D. Greenberg, Jingmei Hsu, Sebastian A. Mayer, Ruben Niesvizky, Roger N. Pearse, Adrienne A. Phillips, Adriana Rossi, Morton Coleman, Koen van Besien & Tsiporah B. Shore. (2019) High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation 54:12, pages 2027-2038.
Crossref
Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong & Karthik Ramasamy. (2016) Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma. Biology of Blood and Marrow Transplantation 22:11, pages 1926-1937.
Crossref
K A Kasow, C F Stewart, R C Barfield, N L Wright, C Li, D K Srivastava, W Leung, E M Horwitz, L C Bowman, R Handgretinger & G A Hale. (2012) A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up. Bone Marrow Transplantation 47:11, pages 1448-1454.
Crossref
ZHENGGUANG LI, XINGYI LI, ZHIXING CAO, YOUZHI XU, HONGJUN LIN, YINGLAN ZHAO, YUQUAN WEI & ZHIYONG QIAN. (2012) Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: Efficient suppression of growth of multiple myeloma in a murine model. Oncology Reports 27:4, pages 1035-1040.
Crossref
Omar S Aljitawi & Joseph P McGuirk. (2012) Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what’s new?. Journal of Comparative Effectiveness Research 1:1, pages 57-70.
Crossref
Janelle B. Perkins, Steven C. Goldstein, Jana L. Dawson, Jongphil Kim, Teresa L. Field, James S. Partyka, Karen K. Fields, Beth L. Maddox, Christine E. Simonelli, Anthony M. Neuger, Richard M. Lush & Daniel M. Sullivan. (2011) Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates. Clinical Cancer Research 17:24, pages 7743-7753.
Crossref
P Moreau, M Attal & J L Harousseau. (2011) New developments in conditioning regimens before auto-SCT in multiple myeloma. Bone Marrow Transplantation 46:7, pages 911-915.
Crossref
Christos Kosmas, Theodoros Daladimos, Aggelos Athanasopoulos, Evangelos Theotikos, George Tsakonas, Athanasios Karabelis & Nikolaos Mylonakis. (2010) Double high-dose chemotherapy and stem cell transplantation in adult Wilms’ tumor. Future Oncology 6:11, pages 1803-1809.
Crossref
M R Litzow, P P Peethambaram, S L Safgren, G L Keeney, S M Ansell, A Dispenzieri, M A Elliott, D A Gastineau, M A Gertz, D J Inwards, M Q Lacy, I N M Micallef, L F Porrata, W L Lingle, L C Hartmann, M H Frost, B A Barrette, H J Long, V J Suman, J M Reid, M M Ames & S H Kaufmann. (2009) Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplantation 45:3, pages 490-497.
Crossref
Erica Campagnaro, Rima Saliba, Sergio Giralt, Linda Roden, Floralyn Mendoza, Ana Aleman, Charles Cleeland, Donna Weber, Jane Brown & Karen O. Anderson. (2008) Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer 112:7, pages 1617-1624.
Crossref
Rita S. Grigoryan, Bo Yang, Nino Keshelava, Jerry R. Barnhart & C. Patrick Reynolds. (2007) Flow cytometry analysis of single‐strand DNA damage in neuroblastoma cell lines using the F7‐26 monoclonal antibody. Cytometry Part A 71A:11, pages 951-960.
Crossref
Muzaffar H. Qazilbash, Rima M. Saliba, Bilal Ahmed, Gaurav Parikh, Floralyn Mendoza, Noman Ashraf, Chitra Hosing, Thuy Flosser, Donna M. Weber, Michael Wang, Daniel R. Couriel, Uday Popat, Partow Kebriaei, Amin M. Alousi, Paolo Anderlini, Rizwan C. Naeem, Richard E. Champlin & Sergio A. Giralt. (2007) Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. Biology of Blood and Marrow Transplantation 13:9, pages 1066-1072.
Crossref
Karen J. Haglof, Elizabeta Popa & Howard S. Hochster. (2006) Recent developments in the clinical activity of topoisomerase-1 inhibitors. Update on Cancer Therapeutics 1:2, pages 117-145.
Crossref
. (2004) Current Awareness in Hematological Oncology. Hematological Oncology 22:2, pages 73-84.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.